Core Viewpoint - Wanfu Bio (300482) has received a medical device registration certificate from the National Medical Products Administration for a combined test kit for respiratory syncytial virus, adenovirus, and Mycoplasma pneumoniae antigens, marking a significant advancement in the field of respiratory infection diagnostics [1] Group 1 - The newly certified test kit utilizes latex agglutination method for rapid detection of multiple respiratory pathogens [1] - This product is part of the company's strategic expansion in the in vitro diagnostic sector for respiratory infections [1] - The test kit aims to provide a more convenient and efficient solution for clinical diagnosis of respiratory infections [1]

Core Viewpoint - The company Wanfu Bio has received a medical device registration certificate from the National Medical Products Administration for its combined test kit for respiratory syncytial virus (RSV), adenovirus (ADV), and Mycoplasma pneumoniae (MP) antigens, which is expected to positively impact its product offerings and sales growth [1] Group 1 - The product is designed for in vitro qualitative detection of RSV, ADV, and MP antigens in nasopharyngeal swab samples [1] - The approval of the product registration certificate will increase the variety of products available for sale by the company [1] - The company plans to actively promote the sales of the related products, although it is currently unable to predict the impact on future revenue [1]

| 名称 | 注册证号 | 有效期至 | 预期用途 | | --- | --- | --- | --- | | 呼吸道合胞病毒抗 | | | | | 原、呼吸道腺病毒抗 | | | 本产品用于体外定性检测人口咽拭子样本中呼 | | | 国 械 注 准 | | | | 原、肺炎支原体抗原 | | 2030/11/03 | 吸道合胞病毒（RSV）抗原、呼吸道腺病毒（ADV） | | | 20253402231 | | | | 联合检测试剂（乳胶 | | | 抗原、肺炎支原体（MP）抗原。 | | 法） | | | | 本次获证的呼吸道合胞病毒、腺病毒、肺炎支原体联合检测试剂，是公司在 呼吸道感染体外诊断领域的重要产品布局。该产品实现了多种呼吸道病原体的联 合快速检测，能够为临床快速诊断呼吸道感染提供更便捷、高效的解决方案，进 一步丰富了公司呼吸道检测产品线，有助于提升公司在体外诊断行业呼吸道检测 领域的市场竞争力，符合公司长期发展战略。 上述产品获得产品注册证书，将进一步增加公司销售产品的品种，对公司发 展具有正影响，公司未来会积极推动相关产品的销售，目前尚无法预测该产品对 公司未来营业收入的影响，敬请投资者注意 ...

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

Group 1 - The company Wanfu Biology (SZ 300482) announced a share buyback plan, with the actual buyback period from September 26, 2025, to November 21, 2025 [1] - As of November 21, 2025, the company repurchased approximately 1.43 million shares, accounting for 0.3059% of the total share capital, with a total transaction amount of about 30.09 million yuan [1] - The buyback exceeded the lower limit of the planned repurchase quantity and did not exceed the upper limit, indicating the completion of the buyback plan [1] Group 2 - For the year 2024, the revenue composition of Wanfu Biology is as follows: diagnostic products account for 97.59%, while other products account for 2.41% [1] - The current market capitalization of Wanfu Biology is 9.7 billion yuan [1]

Group 1 - The company announced a share repurchase program with the actual repurchase period set from September 26, 2025, to November 21, 2025 [2] - As of November 21, 2025, the company has repurchased a total of 1,431,679 shares, which represents 0.3059% of the company's total share capital [2]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于回购公司股份实施结果暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开的第五届董事会第十四次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式回购公司已发行的人民币普通股股 份，用于员工持股计划和股权激励。本次用于回购股份的资金总额不低于人民币 3,000 万元且不超过人民币 6,000 万元（均包含本数），回购价格不超过人民币 34.66 元/股（含），回购实施期限自公司董事会审议通过本次回购方案之日起 6 个月内。具体内容详见公司刊登在中国证监会指定创业板信息披露网站上的相关 公告。 截至 2025 年 11 月 24 日，公司本次回购股份方案已实施完毕。根据《上市 公司股份回购规则》、《深圳证券交易所 ...

Core Viewpoint - Wanfu Biological experienced a slight decline in stock price, with significant financing activities indicating high levels of trading activity and investor interest [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Wanfu Biological reported a revenue of 1.69 billion yuan, representing a year-on-year decrease of 22.52% [2]. - The net profit attributable to shareholders for the same period was 134 million yuan, down 69.32% year-on-year [2]. Group 2: Shareholder and Financing Information - As of November 20, 2023, the total financing and securities lending balance for Wanfu Biological was 488 million yuan, with a financing net buy of -1.22 million yuan on that day [1]. - The number of shareholders decreased to 42,400, a reduction of 5.59% compared to the previous period, while the average circulating shares per person increased by 5.94% to 10,160 shares [2]. - The company has distributed a total of 1.213 billion yuan in dividends since its A-share listing, with 601 million yuan distributed over the past three years [3]. Group 3: Business Overview - Wanfu Biological, established on November 13, 1992, and listed on June 30, 2015, specializes in the research, production, and sales of rapid diagnostic reagents and instruments related to point-of-care testing (POCT) [1]. - The company's revenue composition includes chronic disease testing (45.93%), infectious disease testing (30.93%), drug abuse testing (11.82%), pregnancy and reproductive health testing (11.27%), and other supplementary tests (0.04%) [1].

Group 1 - The company, Wanfu Biology (300482), stated on November 19 that it strictly adheres to information disclosure regulations in response to investor inquiries [1]

Core Viewpoint - Wanfu Biology (300482.SZ) has announced that it currently does not have any products for detecting rhinoviruses, but is responding to the potential flu peak by launching an integrated respiratory pathogen detection solution that combines reagents, instruments, and information systems to reduce patient wait times and assist medical institutions in managing the flu testing peak [1] Group 1 - The company is introducing a comprehensive solution aimed at addressing the characteristics of the current flu season [1] - The solution is designed to shorten patient waiting times and support healthcare institutions in handling the peak of flu testing [1] - The company has both online and offline sales and promotion channels to meet market demands [1] Group 2 - The company's operational strategy will adjust according to market demand [1]